Nalu Medical – a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain – announced the closing of an incremental $20 million in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85 million.
Novo Holdings led the Series E funding round, with $65 million of the total closing in late December 2023. And also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
The funding proceeds will accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations. And Nalu will continue to invest in building clinical data that provide physicians with clear evidence of its benefits while also serving as the basis for expanded access and payor coverage.
KEY QUOTES:
“The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain. We believe that our highly capable technology and uniquely small implant will elevate the standard of care in peripheral nerve stimulation (PNS) while being disruptive to the established spinal cord stimulation (SCS) market. We are proud that our efforts serve the greater well-being of patients who suffer from chronic pain, and we are grateful for B Capital’s support in fulfilling and accelerating our mission.”
- Tom West, President and CEO of Nalu
“The unique, clinically proven Nalu Neurostimulation System has the potential to address the unmet needs of millions who suffer from chronic neuropathic pain. We look forward to partnering with Nalu’s talented management team and strong syndicate of investors at a time of high revenue growth and potential for the company.”
- Dr. Robert Mittendorff, Head of Healthcare and General Partner at B Capital
